NNC0471-0119 H insulin: pump pharmacology study
What this study tests
A completed Novo Nordisk phase 1 crossover study comparing the action of investigational insulin NNC0471-0119 H when delivered by pump. It measures early glucose-lowering activity under controlled clamp conditions.
Editorial review: . What was checked and what remains uncertain.
Registry checked: 2026-09-16. Registry’s own update: 2026-09-10.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews.
Evidence at a glance
- Who can enter the study?
- Adults aged 18–64 with T1D for at least one year, pump use for at least 90 days and insulin requirements of 0.2–1.2 units/kg/day. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- The registry records 43 participants and completion in July 2025, but no results are posted. Completion does not establish that the insulin is faster, safer or available. The primary measure is glucose infusion needed during the first hour after a bolus.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: European Union. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read this trial’s review notes for the checks completed and what remains unresolved. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- AUC(GIR,0-1h,basal-corrected): Area under the basal-corrected glucose infusion rate (GIR)-time curve from 0 to 1 hour — 0 to 1 hour after bolus infusion
The full picture
What the study asks
A completed Novo Nordisk phase 1 crossover study comparing the action of investigational insulin NNC0471-0119 H when delivered by pump. It measures early glucose-lowering activity under controlled clamp conditions.
Who it involves
Adults aged 18–64 with T1D for at least one year, pump use for at least 90 days and insulin requirements of 0.2–1.2 units/kg/day. This is a summary; the full registry lists additional criteria.1
Design and timing
The registry lists 43 participants (actual enrollment). Primary completion: 2025-07-16 (actual). Study completion: 2025-07-28 (actual). Estimated dates can change and do not mean results are available.1
Evidence and limits
The registry records 43 participants and completion in July 2025, but no results are posted. Completion does not establish that the insulin is faster, safer or available. The primary measure is glucose infusion needed during the first hour after a bolus.
References
-
ClinicalTrials.gov. NCT06809621. Record checked 16 September 2026; last update posted 2026-09-10. https://clinicaltrials.gov/study/NCT06809621 ↩ ↩2
Sources
- [1]A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump (NCT06809621) · registry — Protocol and current registry status checked 16 September 2026.